Targeting cMET with INC280 impairs tumour growth and improves efficacy of gemcitabine in a pancreatic cancer model
出版年份 2015 全文链接
标题
Targeting cMET with INC280 impairs tumour growth and improves efficacy of gemcitabine in a pancreatic cancer model
作者
关键词
Pancreatic cancer, cMET, Resistance, Survival
出版物
BMC CANCER
Volume 15, Issue 1, Pages -
出版商
Springer Nature
发表日期
2015-02-18
DOI
10.1186/s12885-015-1064-9
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- STAT5b as Molecular Target in Pancreatic Cancer—Inhibition of Tumor Growth, Angiogenesis, and Metastases
- (2015) Christian Moser et al. NEOPLASIA
- European cancer mortality predictions for the year 2013
- (2013) M. Malvezzi et al. ANNALS OF ONCOLOGY
- Inhibiting the Interaction of cMET and IGF-1R with FAK Effectively Reduces Growth of Pancreatic Cancer Cells in vitro and in vivo
- (2013) Deniz A. Ucar et al. Anti-Cancer Agents in Medicinal Chemistry
- Cancer statistics, 2013
- (2013) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Crizotinib Inhibits Metabolic Inactivation of Gemcitabine in c-Met-driven Pancreatic Carcinoma
- (2013) A. Avan et al. CANCER RESEARCH
- The novel c-Met inhibitor cabozantinib overcomes gemcitabine resistance and stem cell signaling in pancreatic cancer
- (2013) C Hage et al. Cell Death & Disease
- Postoperative Prognostic Predictors of Pancreatic Ductal Adenocarcinoma: Clinical Analysis and Immunoprofile on Tissue Microarrays
- (2012) Joo Kyung Park et al. ANNALS OF SURGICAL ONCOLOGY
- HIF-1 activation induces doxorubicin resistance in MCF7 3-D spheroids via P-glycoprotein expression: a potential model of the chemo-resistance of invasive micropapillary carcinoma of the breast
- (2012) Sophie Doublier et al. BMC CANCER
- Current concepts and novel targets in advanced pancreatic cancer
- (2012) Patrick Michl et al. GUT
- Targeting the Hepatocyte Growth Factor–cMET Axis in Cancer Therapy
- (2012) George R. Blumenschein et al. JOURNAL OF CLINICAL ONCOLOGY
- Met Receptor Tyrosine Kinase Signaling Induces Secretion of the Angiogenic Chemokine Interleukin-8/CXCL8 in Pancreatic Cancer
- (2012) Kristen S. Hill et al. PLoS One
- Developments in metastatic pancreatic cancer: Is gemcitabine still the standard?
- (2012) Jie-Er Ying WORLD JOURNAL OF GASTROENTEROLOGY
- A Novel Kinase Inhibitor, INCB28060, Blocks c-MET-Dependent Signaling, Neoplastic Activities, and Cross-Talk with EGFR and HER-3
- (2011) X. Liu et al. CLINICAL CANCER RESEARCH
- c-Met Is a Marker of Pancreatic Cancer Stem Cells and Therapeutic Target
- (2011) Chenwei Li et al. GASTROENTEROLOGY
- Targeting FGFR/PDGFR/VEGFR Impairs Tumor Growth, Angiogenesis, and Metastasis by Effects on Tumor Cells, Endothelial Cells, and Pericytes in Pancreatic Cancer
- (2011) J. Taeger et al. MOLECULAR CANCER THERAPEUTICS
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Expression and Prognostic Significance of CD151, c-Met, and Integrin alpha3/alpha6 in Pancreatic Ductal Adenocarcinoma
- (2010) Guang-Hui Zhu et al. DIGESTIVE DISEASES AND SCIENCES
- Stromal biology and therapy in pancreatic cancer
- (2010) A. Neesse et al. GUT
- Advanced pancreatic carcinoma: current treatment and future challenges
- (2010) Anastasios Stathis et al. Nature Reviews Clinical Oncology
- Modeling Pancreatic Cancer In Vivo
- (2010) Yongzeng Ding et al. PANCREAS
- MetMAb, the One-Armed 5D5 Anti-c-Met Antibody, Inhibits Orthotopic Pancreatic Tumor Growth and Improves Survival
- (2008) H. Jin et al. CANCER RESEARCH
- Targeting heat-shock protein 90 improves efficacy of rapamycin in a model of hepatocellular carcinoma in mice
- (2008) Sven A. Lang et al. HEPATOLOGY
- Dual targeting of Raf and VEGF receptor 2 reduces growth and metastasis of pancreatic cancer through direct effects on tumor cells, endothelial cells, and pericytes
- (2008) S. A. Lang et al. MOLECULAR CANCER THERAPEUTICS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started